Inside a University of Utah laboratory, researchers noticed something odd about a family affected by a devastating seizure disorder. Some relatives carried the exact genetic mutation that should have destroyed their lives, yet they lived without symptoms. Their DNA held a secret that could revolutionize the way we treat epilepsy.
At the same time, across different research teams, another puzzle emerged. Aging fruit flies were developing brain changes that looked disturbingly similar to what happens in human brains with seizure disorders. Both discoveries pointed to proteins that act as neural guardians, protecting brain cells from electrical chaos.
One in 10 Americans lives with a rare disease. Most of these conditions lack treatments beyond symptom management. PIGA-CDG represents one of these medical mysteries, an ultra-rare genetic disorder that triggers seizures and developmental delays from early childhood. Until now, families affected by PIGA-CDG have had few options and fewer answers about why some patients suffer more than others.
Recent research has identified two proteins that prevent seizures through different mechanisms. One blocks the disease process directly. Another maintains brain health during aging, when seizure risk climbs. Both findings offer new paths toward treatments that could help millions of people.
When Genetics Should Predict Disease But Doesn’t
PIGA-CDG stems from mutations in a gene called PIGA. Every person diagnosed with the disorder carries changes to that gene. Logic suggests that identical mutations should produce identical outcomes, yet some patients experience mild symptoms while others face severe disability.
Holly Thorpe and senior author Clement Chow, PhD, at the University of Utah Health, suspected that secondary genetic factors must explain the variation. In one family they studied, several members carried the disease-causing PIGA mutation but showed no symptoms at all. Their bodies had found a way to compensate.
Standard genetic analysis techniques work well when you have thousands of patients to study. With ultra-rare diseases affecting only a handful of families worldwide, those methods fail. Researchers needed a different approach.
They created a shortlist of genes that differed between sick and healthy family members, then turned to an unlikely ally: Drosophila melanogaster, the common fruit fly. Scientists have mapped every gene in the fly genome and can manipulate them with precision.
Flies with reduced PIGA function in their neurons develop seizures and struggle to move. Researchers gave these flies additional genetic changes that matched what they found in the protected human family members. One combination produced remarkable results.
When flies had reduced PIGA function alongside reduced function of a gene called CNTN2, they moved more freely. Their seizures decreased in severity. CNTN2, which codes for the protein Contactin 2, appeared to protect against PIGA-CDG.
“If we can use this strategy more broadly, I think we can help address the problem of phenotypic variation in rare disease,” says Chow, associate professor of genetics in the Spencer Fox Eccles School of Medicine at University of Utah Health. “I am hoping that this will be used as a roadmap moving forward.”
How Contactin 2 Guards Neural Circuits
Contactin 2 belongs to a family of proteins that help neurons connect and communicate. Found on cell surfaces, these proteins guide growing nerve fibers to their targets during brain development. They also maintain connections between mature neurons throughout life.
In normal brains, CNTN2 helps organize neural circuits and stabilize synapses where signals pass between cells. When PIGA mutations disrupt cellular function, altered CNTN2 appears to compensate by modifying how neurons respond to stress.
Researchers believe the protective CNTN2 variant in the healthy family members changes how their neurons handle the metabolic problems caused by PIGA mutations. Instead of becoming hyperexcitable and prone to seizures, their neurons maintain more stable electrical activity.
For patients with PIGA-CDG, identifying CNTN2 as a disease modifier opens several therapeutic possibilities. Drugs that mimic the protective effects of altered CNTN2 could reduce seizures without fixing the underlying PIGA mutation. Gene therapy approaches might introduce the protective CNTN2 variant directly into patient neurons.
Aging Brains Accumulate a Seizure Trigger
While Utah researchers studied rare childhood seizures, a team at UCLA investigated why elderly brains become prone to seizures and cognitive decline. What they found connects to a structural protein present in every cell.
Actin gives cells their shape and enables movement. It exists in two forms: individual molecules called G-actin and long chains called filamentous actin or F-actin. Cells constantly assemble and disassemble these filaments as needed for different tasks.
Edward (Ted) Schmid and David Walker, PhD, noticed that F-actin accumulates in aging fruit fly brains. Young flies had modest amounts. Older flies showed extensive F-actin buildup, forming rod-like structures never seen in youth.
Correlation doesn’t prove causation, so researchers tested whether F-actin directly harms aging brains. They used genetics to target genes controlling actin filament formation, including one called Fhos that helps assemble F-actin chains.
Reducing Fhos expression in aging neurons prevented F-actin accumulation in the brain. Even though researchers only modified neurons, the change improved overall fly health. Treated flies lived 25 to 30 percent longer while showing better brain function and health markers in other organs.
“Flies get more forgetful as they age, and their ability to learn and remember declines in middle age, just like it does in people,” Walker explains. “If we prevent accumulation of F-actin, it helps the flies learn and remember when older, which tells us the buildup is not benign.”
Memory tests confirmed the connection. Young flies easily learned to avoid an odor paired with electric shocks. Aged flies performed poorly on the same test. But aged flies with reduced F-actin showed memory recall as good as young flies.
Cellular Garbage Disposal Gets Clogged
Why does F-actin buildup damage aging brains? Researchers discovered it interferes with autophagy, the process cells use to break down and recycle damaged components. Aging research has long shown that autophagy declines with age, but nobody knew exactly why.
F-actin filaments physically block the movement of autophagosomes, specialized vesicles that engulf cellular garbage and transport it to lysosomes for breakdown. When F-actin accumulates, autophagosomes can’t reach their destination. Waste piles up inside neurons.
Accumulated debris includes damaged proteins, dysfunctional mitochondria, and other cellular junk. Old mitochondria leak reactive molecules that damage surrounding structures and make neurons hyperexcitable. Protein aggregates interfere with normal cellular operations. Both problems increase seizure susceptibility.
Preventing F-actin accumulation restored autophagy in aging fly brains. Treated flies had fewer protein aggregates, healthier mitochondria, and better mitochondrial membrane potential, indicating efficient energy production.
Remarkably, treating middle-aged flies with cytochalasin D, a drug that breaks apart actin filaments, reversed brain aging markers. After one week of treatment, aged flies had better autophagy, fewer protein aggregates, and less accumulated mitochondrial debris than before treatment began. Brain function improved along with cellular health.
Two Proteins, One Goal
CNTN2 and Fhos may seem unrelated, but both protect against seizures by maintaining neuronal health. CNTN2 compensates for metabolic defects in rare genetic diseases. Fhos, when kept in check, prevents the cellular dysfunction that makes aging brains prone to seizures and cognitive decline.
Both discoveries highlight how multiple factors determine seizure risk beyond obvious disease genes. Genetic background matters in inherited epilepsies. Cellular maintenance processes matter in age-related seizure disorders. Understanding these protective mechanisms reveals new treatment targets.
For PIGA-CDG patients, drugs that enhance CNTN2 function or mimic its protective effects could reduce seizures and improve development. Current treatments only manage symptoms after they appear. CNTN2-targeted therapies might prevent damage before it starts.
For age-related seizure disorders, interventions that prevent F-actin accumulation could maintain brain health during aging. Several drugs already disrupt actin polymerization, though most have side effects that limit their use. Newer compounds that specifically target excess neuronal F-actin could provide benefits without widespread disruption.
Research in both areas faces challenges. PIGA-CDG affects too few patients for traditional clinical trials. Investigators must find creative ways to test whether CNTN2 modulation helps human patients. Age-related interventions require long studies to prove benefits and safety.
From Fruit Flies to Future Medicine
Fruit flies and humans are separated by 800 million years of evolution, yet we share most basic cellular machinery. Neurons work similarly across species. Autophagy follows the same steps. Actin behaves identically. Seizures involve the same electrical disruptions.
Researchers can test hundreds of genetic changes in flies within months, something impossible in human studies. When fly experiments identify protective genes like CNTN2 or harmful processes like F-actin accumulation, the findings often translate to human biology.
Combining human genetic analysis with fly experiments proved powerful for PIGA-CDG. Pedigree studies narrowed possibilities to a manageable number. Fly experiments tested each candidate quickly and cheaply. Without flies, researchers might still be searching for the protective gene.
Walker’s team plans to investigate whether F-actin accumulation occurs in aging human brains and contributes to cognitive decline and seizure disorders in people. If human brains show similar changes, drugs targeting actin dynamics might help millions of elderly patients.
Both research teams emphasize that their findings represent starting points rather than finished treatments. Years of work remain before these discoveries help patients. But after decades with limited options, families affected by rare seizure disorders and age-related epilepsy finally have new directions to explore.
Rare diseases affect 30 million Americans, yet PIGA-CDG patients number in the dozens worldwide. Research on such small populations rarely attracts investment. Yet Chow’s strategy works for any rare disease where some patients fare better than others. Scientists can identify protective genes in small families, then use model organisms to understand how those genes work. Each discovery expands our toolkit for preventing seizures and other neurological problems.
